Cardiovascular Clinical Studies, Inc.   Report issue

For profit Phase 2 Phase 3
Founded: Boston MA United States (1996)
Status: No NME R&D (1996)

Organization Overview

First Clinical Trial
2004
NCT00132886
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2007

Timeline

NOW
  • Now

Alternative names

Cardiovascular Clinical Studies | Cardiovascular Clinical Studies and Tufts/New England Medical Center

Active Ingredients

Drugs in Phase 3 Trials (1)

carvedilol (coreg) (1 trial)

Drugs in Phase 2 Trials (2)

alagebrium (1 trial)

tolvaptan (samsca) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Heart Failure (Phase 3)

Heart Failure, Diastolic (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 3